Últimas noticias sobre DarioHealth (NASDAQ:DRIO) Bolsa

DarioHealth

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

DarioHealth Corp

TD Securities analyst Andrew Charles reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and maintains $90 price target.

News

Price Target

Reiteration

Analyst Ratings

SBUX

TD Securities Reiterates Hold on Starbucks, Maintains $90 Price Target

Global Medical REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) today announced that Mark Decker, Jr. has been appointed as the Company's Chief Executive Officer and President, effective immediately. Mr. Decker, who will join the Board of Directors, succeeds Jeffrey Busch, who will continue to serve on the Board as non-executive Chairman.
 &nbsp;

Management

GMRE

Global Medical REIT Appoints Mark Decker Jr. As CEO And President, Succeeding Jeffrey Busch, Effective Immediately

NPKI

NPK International Secures $150M Revolving Credit Facility With Five-Year Term

JP Morgan analyst Anthony Paolone downgrades Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) from Overweight to Neutral and lowers the price target from $24 to $21.

Downgrades

COLD

JP Morgan Downgrades Americold Realty Trust to Neutral, Lowers Price Target to $21

<ul>
<li>In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone</li>
<li>Icovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube cultures</li>
<li>In severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last dose</li>
</ul>

Biotech

Health Care

General

BMEA

Biomea Fusion Announced The Presentation Of New Preclinical And Clinical Data For Icovamenib At The Scientific Sessions Of The American Diabetes Association

IAMGOLD Says Côté Gold Mine Reaches Major Milestone As Processing Plant Operated At Nameplate Capacity Of 36,000 tpd On Average Over Thirty Consecutive Days

Needham analyst Chris Pierce reiterates CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Buy and maintains $92 price target.

Needham Reiterates Buy on CarMax, Maintains $92 Price Target

PTCT

PTC's Sephience Authorized In EU For All Phenylketonuria Patient Segments, Launching In Germany With FDA Decision Pending July 29

<ul>
<li>The study met its primary and all secondary efficacy endpoints for all dose groups</li>
<li>Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo</li>
<li>CD388 was well-tolerated with no safety signals observed</li>
<li>End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA)</li>
</ul>

CDTX

Cidara Therapeutics Announces Topline Results From Its Phase 2B NAVIGATE Trial Of CD388 For Seasonal Influenza In Healthy Unvaccinated Adults Aged 18 To 64, The Study Met Its Primary Endpoint, Demonstrating A Statistically Significant Prevention Efficacy For Each Of Three Dose Groups

JP Morgan analyst Michael Mueller upgrades Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Overweight and raises the price target from $70 to $72.

Upgrades

JP Morgan Upgrades Ventas to Overweight, Raises Price Target to $72

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash&nbsp;&nbsp;
Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business &nbsp; Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even &nbsp; Cash &amp; Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina"), including SomaScan&#xAE; Assay Services, Authorized Sites and KREX&#x2122; for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep). Standard BioTools will retain certain Single SOMAmer reagent commercialization rights. The transaction significantly simplifies the operating structure of Standard BioTools and enables the achievement of adjusted EBITDA break-even.
The transaction is expected to close in the first half of 2026, subject to receipt of required regulatory approvals, including receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and satisfaction of other customary closing conditions. The transaction has been unanimously approved by both the Standard BioTools Board of Directors and a Special Committee of the Standard BioTools Board of Directors.

ILMN

Standard BioTools Sells SomaLogic To Illumina For Up To $425M, Plus Future Royalties

<ul>
<li>Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site</li>
<li>Evidence of retinal structural improvement persisted out to 3 years</li>
<li>Anatomical and functional improvements occur following a single administration of OpRegen cell therapy</li>
</ul>

LCTX

Lineage's OpRegen Shows +9 Letter BCVA Gains At 3 Years With Extensive Cell Coverage In Phase 1/2a Trial For Geographic Atrophy

Fermium Research analyst Frank Mitsch downgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Buy to Hold and announces $30 price target.

Fermium Research Downgrades Dow to Hold, Announces $30 Price Target

JP Morgan analyst Anthony Paolone downgrades Howard Hughes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) from Overweight to Neutral and lowers the price target from $82 to $76.

JP Morgan Downgrades Howard Hughes Holdings to Neutral, Lowers Price Target to $76

LPTX

Leap Therapeutics Has Initiated The Process To Explore Strategic Alternatives

JP Morgan analyst Alexei Gogolev downgrades CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) from Neutral to Underweight and announces $10 price target.

CCCS

JP Morgan Downgrades CCC Intelligent Solutions to Underweight, Announces $10 Price Target

<ul>
<li>PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history</li>
<li>Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range</li>
<li>Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression</li>
<li>Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026</li>
</ul>

PASG

Passage Bio Reports Interim Data From upliFT-D Showing Durable CSF PGRN Elevation And Reduced Plasma NfL Versus Natural History In FTD-GRN

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups

Leap Therapeutics Reports Updated Results From Part B Of DeFianCe Phase 2 Study Of Sirexatamab In Combination With Bevacizumab And Chemotherapy Vs. Bevacizumab And Chemotherapy For Advanced Microsatellite Stable Colorectal Cancer

Innovative MicroLED Manufacturing Method Promises Greater Efficiency and Reusability
MANCHESTER, England, June 23, 2025 /PRNewswire/ -- Smartkem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>), which is seeking to change the world of electronics with a new class of transistor technology, today announced that it has received a UK patent for a new method for MicroLED display manufacturing, adding to its extensive IP portfolio. The new patent covers the patterning of an organic thin-film transistor (OTFT) backplane on top of, and selective removal of MicroLEDs from, a source wafer.

SMTK

Smartkem Receives UK Patent For New Method For MicroLED Display Manufacturing

SOXX reverses early weakness after alert from TradePulse
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/20204032/Screenshot-2025-06-20-at-4.37.31%E2%80%AFPM-1012x1024.png" alt="" class="wp-image-14711" /></figure>
Ishares Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:51 AM on June 20th, a significant trading signal occurred for Ishares Semiconductor ETF, (SOXX) as it demonstrated a Power Inflow at a price of $222.86. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in iShares&#8217; stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in the iShares' stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for SOXX, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $222.86. The returns on the High price ($225.50) and Close price ($225.11) after the Power Inflow are respectively 1.2% and 1.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Results are not indicative of Future results.

Technicals

Opinion

Signals

Trading Ideas

ETFs

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Semi ETF SOXX Climbs 1.2% After Key Trading Signal

Small Cap

Press Releases

/C O R R E C T I O N -- DarioHealth Corp./

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth

Contracts

Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion

DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Penny Stocks

DarioHealth Announces CFO Transition

DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

Earnings

DarioHealth Reports First Quarter 2025 Financial and Operating Results

Market Alert: DarioHealth Receives $3 Price Target and Buy Rating: Everything You Need to Know

Comments

DarioHealth

Noticias

Últimas noticias sobre DarioHealth (NASDAQ:DRIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL